Breast Cancer Drug Boost
Raloxifene and breast cancer. There has been a great deal of press interest recently in whether the osteoporosis drug Raloxifene can have an impact on the outcome for breast cancer patients. But what’s the evidence? Does this drug reduce the risk of invasive breast cancer?
The new drug called Tykerb, couple with chemotherapy, has show in clinical trials to do a better job of fighting breast cancer than chemo alone.
This was a large study and it backs up other reports which also seem to show a benefit from Raloxifene in terms of breast cancer in women after the menopause. The latter point here may be important - after the menopause.
According the HealthDay News, Tamoxifen has been in widespread use among breast cancer survivors for the last two decades. The drug is typically taken after surgery, because it targets the hormone estrogen, which can promote tumor cell growth in women with estrogen-sensitive breast cancer. A standard five-year treatment of tamoxifen has been found to reduce breast cancer death rates by as much as 31 percent.
Although this medication may go on to save the lives of many women, the FDA should not allow companies who have interest in the outcome of the study be the one who funds and conducts it. Anyone who has interest in the outcome of any event will always do what is in their power to protect their interest. Like the old adage goes. ?You ain?t cheatin, You ain?t tryin .?
